Molecular signature of different lesion types in the brain white matter of patients with progressive multiple sclerosis

Autor: Torben A Kruse, Mads Thomassen, Jan Baumbach, Zsolt Illes, Tobias Frisch, Tim Kacprowski, Richard Reynolds, Mark Burton, Maria L. Elkjaer
Rok vydání: 2019
Předmět:
Immunoglobulin gene
Pathology
medicine.medical_specialty
Context (language use)
Biology
lcsh:RC346-429
Pathology and Forensic Medicine
Multiple sclerosis
Lesion
White matter
03 medical and health sciences
Cellular and Molecular Neuroscience
0302 clinical medicine
Gene expression
medicine
Humans
TGF-beta
lcsh:Neurology. Diseases of the nervous system
030304 developmental biology
0303 health sciences
Microglia
Sequence Analysis
RNA
Research
Gene Expression Profiling
Receptor
Transforming Growth Factor-beta Type II
Brain
High-Throughput Nucleotide Sequencing
Multiple Sclerosis
Chronic Progressive
medicine.disease
White Matter
ddc
3. Good health
CD26/DPP4
Next-generation RNA sequencing
medicine.anatomical_structure
Human brain lesions
Immunohistochemistry
Secondary progressive
Neurology (clinical)
medicine.symptom
030217 neurology & neurosurgery
Zdroj: Acta Neuropathologica Communications
Acta Neuropathologica Communications, Vol 7, Iss 1, Pp 1-17 (2019)
Elkjaer, M L, Frisch, T, Reynolds, R, Kacprowski, T, Burton, M, Kruse, T A, Thomassen, M, Baumbach, J & Illes, Z 2019, ' Molecular signature of different lesion types in the brain white matter of patients with progressive multiple sclerosis ', Acta Neuropathologica Communications, vol. 7, 205 . https://doi.org/10.1186/s40478-019-0855-7
ISSN: 2051-5960
Popis: To identify pathogenetic markers and potential drivers of different lesion types in the white matter (WM) of patients with progressive multiple sclerosis (PMS), we sequenced RNA from 73 different WM areas. Compared to 25 WM controls, 6713 out of 18,609 genes were significantly differentially expressed in MS tissues (FDR n = 2213), remyelinating lesions had the highest gene expression levels, and the most different molecular map from chronic active lesions. This may suggest that these two lesion types represent two ends of the spectrum of lesion evolution in PMS. The profound changes in chronic active lesions, the predominance of synaptic/neural/axonal signatures coupled with minor inflammation may indicate end-stage irreversible molecular events responsible for this less treatable phase.
Databáze: OpenAIRE
Externí odkaz: